The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

Healthcare costs are expected to rise by nearly 8% in 2025 ... In addition, more people are using GLP-1 weight loss drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to treat diabetes, obesity ...

The digital health market is welcoming new IPOs for the first time in years. Bankers and investors think these 9 startups ...

The high monthly costs of GLP-1s — ranging from $1,000 to $1,500 — are placing considerable financial pressure on healthcare plans.

School districts across Minnesota are struggling to contain double-digit health insurance cost increases. Some officials say ...

This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

Many health and wellness stocks have faced challenges in recent years as GLP-1 weight-loss drugs like Ozempic and Wegovy ...

Why Some People Are Microdosing Popular Weight-Loss Drugs Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects By Sumathi Reddy Share ...

Ozempic could help with his as a study by Goldman Sachs found that the mass-adoption of GLP-1 series drugs could allow for large-scale economic growth and increase the United States Gross Domestic ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Unions blame ‘greed’ by healthcare providers, state officials say pricey weight-loss meds and increasing demand for care are the problem.

CBIZ Report Highlights Rising Costs: Surge in Inpatient and Outpatient Expenses, Popular GLP-1 Drugs like Ozempic Drive Pharmacy Spend Increase New CBIZ State of Healthcare Report Reveals Cost ...